8月20日晚间,恒瑞医药(600276.SH;01276.HK)发布2025年半年度报告,上半年实现营业收入157.61亿元,同比增长15.88%;归属于上市公司股东的净利润44.50亿元,同比大幅增长29.67%;经营活动产生的现金流量净额达43.00亿元,同比增长41.80%。营收、净利及经营性现金流净额均创历史同期新高,展现出稳健的增长态势。业绩驶入“快车道”,创新药内生增长占比突破六成...
Source Link8月20日晚间,恒瑞医药(600276.SH;01276.HK)发布2025年半年度报告,上半年实现营业收入157.61亿元,同比增长15.88%;归属于上市公司股东的净利润44.50亿元,同比大幅增长29.67%;经营活动产生的现金流量净额达43.00亿元,同比增长41.80%。营收、净利及经营性现金流净额均创历史同期新高,展现出稳健的增长态势。业绩驶入“快车道”,创新药内生增长占比突破六成...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.